Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acthar Gel for Treatment-Resistant Idiopathic FSGS
NCT02633046Phase 4Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Oct 2016
- Primary completion
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
A Phase 4 trial of repository corticotropin injection in focal segmental glomerulosclerosis (FSGS), sponsored by Mallinckrodt Pharmaceuticals. Started Oct 2016; status: completed.
02
Drugs
repository corticotropin injection
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT02633046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633046.